In today’s briefing:
- Alteogen (196170 KS): Modified License Agreement For Major Platform Technology Is A Hard Catalyst
- DaVita Inc: 5 Biggest Catalysts Of Their Future Growth! – Financial Forecasts
- Incyte Corporation: Significant Clinical Progress in Pipeline Programs & Other Major Developments – Financial Forecasts
- IQVIA Holdings: Industry Tailwinds: Rising EBP Funding and Traction in Oncology Space! – Major Drivers
Alteogen (196170 KS): Modified License Agreement For Major Platform Technology Is A Hard Catalyst
- Alteogen Inc (196170 KS) has modified the existing license agreement with Merck. Revised terms of the agreement grant Merck exclusive global right to ALT-B4 for a specific product group, pembrolizumab.
- Under the terms of the revised agreement, Alteogen will receive an upfront payment of $20M from Merck. Alteogen will also receive additional milestone payment of up to $432M.
- Approval of Alteogen’s first proprietary product, Tergase (expected in early 2024) will be the next major catalyst for the company.
DaVita Inc: 5 Biggest Catalysts Of Their Future Growth! – Financial Forecasts
- DaVita, a healthcare company specializing in kidney care and dialysis services, highlights its successful performance for the financial year of 2023 due to strengthening investment on the company’s platform.
- Notably, despite external challenges, the company experienced significant growth with a 20% year-over-year rise in adjusted operating income, a 28% increase in adjusted EPS, and a return of the leverage ratio back to the target range.
- The company outperformed its annual profitability targets for integrated kidney care and anticipates reaching break-even or better performance by 2026.
Incyte Corporation: Significant Clinical Progress in Pipeline Programs & Other Major Developments – Financial Forecasts
- Incyte Corporation’s 2023 earnings have been marked by the firm’s strong performance following a 14% increase in product and royalty revenues compared to 2022, reaching $3.7 billion.
- A significant milestone was achieved in the fourth quarter when total product and royalty revenue reached $1 billion for the first time.
- This growth has primarily been driven by the continued growth of Jakafi and the successful launch of Opzelura.
IQVIA Holdings: Industry Tailwinds: Rising EBP Funding and Traction in Oncology Space! – Major Drivers
- IQVIA displayed a strong performance in the fourth quarter of 2023.
- CEO Ari Bousbib highlighted that net new bookings for the quarter exceeded $2.8 billion, marking the second largest quarter in the company’s history.
- The business booked $10.7 billion of net new business in the year, including record-high service bookings of $8.4 billion.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
